Pharmacologic C5-complement suppression reduces blood loss during on-pump cardiac surgery

Journal of Cardiac Surgery

Volumn 20, Issue 1, 2005, Pages 35-41

  Chen, John C ^a   Rollins, Scott A ^b   Shernan, Stanton K ^c   Boyce, Steven ^d   Allen, Keith ^e   Wallace, Arthur ^f   Malloy, Kevin J ^g   Eng, Jamie S ^a   Colman, Robert W ^h   Fitch, Jane C K ⁱ  

^a UNIVERSITY OF HAWAII   (United States)

^b ALEXION PHARMACEUTICALS   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Washington Regional Cardiac Surgery   (United States)

^e Department of Cardiothoracic Surgery   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^h TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5; FRESH FROZEN PLASMA; PEXELIZUMAB; PLACEBO;

ADULT; AGED; ANTIGEN BINDING; ARTICLE; BLOOD TRANSFUSION; BOLUS INJECTION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRECIPITATE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG INFUSION; ERYTHROCYTE TRANSFUSION; FEMALE; HEART SURGERY; HEART VALVE SURGERY; HEMOLYSIS; HUMAN; INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ON PUMP SURGERY; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE HEMORRHAGE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE TRANSFUSION; TISSUE INJURY; TUBE;

AGED; ANTIBODIES, MONOCLONAL; CARDIOPULMONARY BYPASS; COMPLEMENT C5; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; FEMALE; HEART-LUNG MACHINE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE HEMORRHAGE;

EID: 19944432652     PISSN: 08860440     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0886-0440.2005.200370.x     Document Type: Article

References (29)

1. Wan S, LeClerc J-L, Vincent J-L: Inflammatory response to cardiopulmonary bypass. Chest 1997;112:676-692.
2. Kirklin JK, Westaby S, Blackstone EH, et al: Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983;86:845-857.
3. Hammerschmidt DE, Stroncek DF, Bowers TK, et al: Complement activation and neutropenia occurring during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1980;81:370-377.
4. Chenoweth DE, Cooper SW, Hugli TE, et al: Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphlyatoxins. N Engl J Med 1981;304:497-503.
5. Vallhonrat H, Swinford RD, Ingelfinger JR, et al: Rapid activation of the alternative pathway of complement by extracorporeal membrane oxygenation. ASAIO J 1999;45:113-114.
6. Chen JC, Huynh TN, Serna DL, et al: Alternative pathway of complement is activated during in vitro ventricular assist. J Invest Med 1999;47:502-506.
7. Tofukuji M, Stahl G, Agah A, et al: Anti-C5a monoclonal antibody reduces cardiopulmonary bypass and cardioplegia-induced coronary endothelial dysfunction. J Thorac Cardiovasc Surg 1998;116:1060-1068.
8. Rinder CS, Rinder H, Smith BR, et al: Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 1995;96:1564-1572.
9. Rinder CS, Rinder HM, Smith MJ, et al: Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation. J Thorac Cardiovasc Surg 1999;118:460-466.
10. Vakeva AP, Agah A, Rollins SA, et al: Myocardial infarction and apoptosis after myocardial ischemia and reperfusion-role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998;97:2259-2267.
11. Fitch JCK, Rollins S, Matis L, et al: Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 1999;100:2499-2506.
12. Shernan SK, Fitch JCK, Nussmeier NA, et al: Impact of pexelizumab, a recombinant, humanized, single-chain, anti-c5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Submitted to Annals of Thoracic Surgery, July 2003.
13. Evans MJ, Rollins SA, Wolff DW, et al: In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5. Mol Immunol 1995;32:1183-1191.
14. Thomas TC, Rollins SA, Rother RP, et al: Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996;33:1389-1401.
15. Dreyer WJ, Michael LH, Nguyen T, et al: Kinetics of C5a release in cardiac lymph of dogs experiencing coronary artery ischemia-reperfusion injury. Circ Res 1992;71:1518-1524.
16. Rus HG, Niculescu FI, Shin ML: Role of the C5b-9 complement complex in cell cycle and apoptosis. Immunol Rev 2001;180:49-55.
17. Holloway DS, Summaria L, Sandesara J, et al: Decreased platelet number and function and increased fibrinolysis contribute to post-operative bleeding in cardiopulmonary bypass patients. Thromb Haemost 1988;59:62-67.
18. Liu B, Belboul A, Larsson S, Roberts D: Factors influencing haemostasis and blood transfusion in cardiac surgery. Perfusion 1996;11:131-143.
19. Murray DJ, Despotis GJ: Coagulation problems. In Thuys D, Hillel Z, Schwartz AJ (eds): Textbook of Cardiothoracic Anesthesiology. New York, McGraw-Hill, 2000, pp. 998-1102.
20. Wiedmer T, Esmon CT, Sims PJ: Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase. Blood 1986;68:875-880.
21. Rinder CS, Bonan JL, Rinder HM, et al: Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood 1992;79:1201-1205.
22. Yomo T, Serna DL, Powel LL, et al: Glycoprotein IIb/IIIa receptor inhibitor attenuates platelet aggregation induced by thromboxane A2 during in vitro nonpulsatile ventricular assist circulation. Artif Organs 2000;24:355-361.
23. Oberman HA: Indications and monitoring of use of fresh frozen plasma as a haemostatic agent. Curr Study Hematol Blood Transfus 1986;53:125-132.
24. Spiess BD: The contribution of fibrinolysis to post bypass bleeding. J Cardiothorac Vasc Anesth 1991;5:13-17.
25. Finn A, Morgan BP, Rebuck N, et al: Effects of inhibition of complement activation using recombinant soluble complement receptor 1 on neutrophil CD11b/CD18 and E-selectin expression and release of interleukin-8 and elastase in simulated cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996;111:451-459.
26. Carson SD, Johnson DR: Consecutive enzyme cascades: complement activation at the cell surface triggers increased tissue factor activity. Blood 1990;76:361-367.
27. Lidington EA, Haskard DO, Mason JC: Induction of decay-acclerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury. Blood 2000;96:2784-2792.
28. Sambrano GR, Huang W, Faruqi T, et al: Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol Chem 2000;75:6819-6823.
29. Eagle AK, Guyton RA, Davidoff R, et al: ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol 1999;34:1262-1347.